Cassady JM et al. |
Recent developments in the maytansinoid antitumor agents. |
2004 |
Chem. Pharm. Bull. |
pmid:14709862
|
Okamoto K et al. |
Therapeutic effect of ansamitocin targeted to tumor by a bispecific monoclonal antibody. |
1992 |
Jpn. J. Cancer Res. |
pmid:1517150
|
Tassone P et al. |
In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. |
2004 |
Cancer Res. |
pmid:15231675
|
Helft PR et al. |
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. |
2004 |
Clin. Cancer Res. |
pmid:15240523
|
Tassone P et al. |
Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. |
2004 |
Blood |
pmid:15292058
|
Lu C et al. |
A novel amide N-glycoside of ansamitocins from Actinosynnema pretiosum. |
2004 |
J. Antibiot. |
pmid:15303496
|
Nakao H et al. |
Cytotoxic activity of maytanprine isolated from Maytenus diversifolia in human leukemia K562 cells. |
2004 |
Biol. Pharm. Bull. |
pmid:15305028
|
Li Y et al. |
Binding selectivity of rhizoxin, phomopsin A, vinblastine, and ansamitocin P-3 to fungal tubulins: differential interactions of these antimitotic agents with brain and fungal tubulins. |
1992 |
Biochem. Biophys. Res. Commun. |
pmid:1530630
|
Henry MD et al. |
A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. |
2004 |
Cancer Res. |
pmid:15520207
|
Liu Z et al. |
An API LC/MS/MS quantitation method for ansamitocin P-3 (AP3) and its preclinical pharmacokinetics. |
2004 |
J Pharm Biomed Anal |
pmid:15533675
|
Carter SK |
New drugs under clinical evaluation in the United States. |
1978 |
Cancer Chemother. Pharmacol. |
pmid:155503
|
Smith SV |
Technology evaluation: cantuzumab mertansine, ImmunoGen. |
2004 |
Curr. Opin. Mol. Ther. |
pmid:15663331
|
Liu Z et al. |
Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry. |
2005 |
J Mass Spectrom |
pmid:15674857
|
Lu SX et al. |
Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy. |
2005 |
J Pharm Sci |
pmid:15729708
|
Hanka LJ and Barnett MS |
Microbiological assays and bioautography of maytansine and its homologues. |
1974 |
Antimicrob. Agents Chemother. |
pmid:15825322
|
Fleming MS et al. |
A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugates. |
2005 |
Anal. Biochem. |
pmid:15840500
|
Lazar AC et al. |
Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. |
2005 |
Rapid Commun. Mass Spectrom. |
pmid:15945030
|
Wang L et al. |
Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. |
2005 |
Protein Sci. |
pmid:16081651
|
Smith SV |
Technology evaluation: huN901-DM1, ImmunoGen. |
2005 |
Curr. Opin. Mol. Ther. |
pmid:16121706
|
Frenzel T et al. |
Synthesis of the N-acetylcysteamine thioester of seco-proansamitocin. |
2006 |
Org. Lett. |
pmid:16381586
|